Amarantus Bioscience Holdings Inc (AMBS)

[michelebucks]

Alzheimer’s Emerging Non-Therapeutic Companies

The significant challenge researchers have faced in developing effective drugs to treat Alzheimer’s disease has opened up market opportunities for companies that can facilitate development efforts.

Amarantus has created a blood test, LymPro, to identify biomarkers for Alzheimer’s. In addition to the clinical benefit of enabling physicians to diagnose Alzheimer’s earlier and with more confidence, LymPro can add significant value in Alzheimer’s research. Amarantus may thus become a major provider for pharmaceutical companies interested in testing the effects of their candidate drugs.

Biogen Idec Inc. (BIIB)
$ 421.35 8.00 (1.94%) AMBS